Announcement of the Company's full receipt of cash capital increase in 2022 and the reference date of capital increase

Announcement of not Distributing Dividends in 2021

The Company's Board of Directors resolved to convene the 2022 Annual General Shareholders' Meeting

Announcement of 2021 Consolidated Financial Statements were approved by the Board of Directors

Supplemental announcement-subscription rights to the cash issue forfeited by directors of the Company reaching 50% and made to specific persons

Subscription rights to the cash issue forfeited by directors of the Company reaching 50% and subscription being made available to specific persons

Announcement of calls on unpaid shares of 2022 cash capital increase

TFDA has granted the approval for the active cancer immunotherapy OBI-833 to proceed to a Phase II clinical trial

Supplementary Statements On News Article

Announcement of acquisition of preferred shares of Odeon Therapeutics (Cayman) Limited